

2024



Corporate governance report 2024

Alligator Bioscience AB (publ)

Corporate governance report

Alligator's corporate governance is governed by the Nasdaq Stockholm rules for issuers, the Swedish Corporate Governance Code (the "Code"), the Swedish Companies Act, good practice in the stock market and other applicable rules and recommendations, and Alligator's Articles of Association and internal governing documents. The internal governing documents mainly cover the rules of procedure for the Board, the mandate to the CEO and the terms of reference for financial reporting. Alligator also has a number of policy documents and manuals containing rules and recommendations, laying down principles and providing guidance for Alligator's operations and for its employees.

This corporate governance report has been drawn up in accordance with the rules in the Annual Accounts Act and in the Code. The corporate governance report has been reviewed by Alligator's auditors in accordance with the provisions of the Annual Accounts Act, and the auditor's opinion is included in the auditor's report on page 78-81 of the Annual report for 2024.

Legal structure

Shareholders

At the end of 2024, Alligator had 11,891 shareholders. On 31 December 2024, Alligator has 758,987,130 shares of which 758,209,917 (657,954,290) are ordinary shares with one vote per share and 779,169 (949,850) are series C shares with one-tenth of a vote per share. The total number of votes in Alligator

amounts to 758,287,833 votes. Furthermore, the exercise of warrants in December 2024 increased the number of shares with an additional 1,498,157 shares. Alligator has received the proceeds in December 2024, but the share issue was registered at Bolagsverket on 2 January 2025.

Each ordinary share entitles the holder to one vote and the and series C shares shall carry one-tenth of a vote per share at the Annual General Meeting. Series C shares are not entitled to dividends. Upon the dissolution of Alligator, series C shares shall carry equivalent right to Alligator's assets as other shares, however, not to an amount exceeding the quota value of the share.

Further details of Alligator's shareholder structure, shares etc. are presented on page 13-14 in the Annual report for 2024.


Shareholders' meeting

The shareholders' right to decide on Alligator's affairs is exercised through the supreme decision-making body, the shareholders' meeting (Annual General Meeting or any Extraordinary General Meeting). For example, the meeting decides on changes to the Articles of Association, appoints the Board and the auditors, approves the income statement and balance sheet, releases the Board and CEO from liability, decides on the appropriation of profit/loss, and adopts principles for appointing the Nomination Committee and guidelines for remuneration of senior executives.


Shareholders may raise a given issue for discussion at the shareholders' meeting. Shareholders who wish to exercise this right must submit a written request to the Board. Such requests must normally reach the Board no later than seven weeks before the shareholders' meeting.

The shareholders' meeting is held in Lund, Sweden. Invitations to the Annual General Meeting and any Extraordinary General Meeting which is to discuss changes to the Articles of Association must be sent out no more than six weeks and no later than four weeks before the meeting. Invitations to other Extraordinary General Meetings must be sent out no more than six weeks and no less than three weeks before the meeting. Invitations are published in Post- och Inrikes Tidningar (the Swedish government gazette) and on Alligator's website. The invitations are also advertised in Dagens Industri.

Legal structure



Overview of corporate governance in Alligator



In order to participate in the shareholders' meeting, shareholders must be entered in the register of shareholders maintained by Euroclear Sweden AB no later than six working days before the meeting, notify Alligator no later than the date provided in the meeting invitation. This day may not be a Sunday, other public holiday, Saturday, Midsummer's Eve, Christmas Eve or New Year's Eve and may not be earlier than five working days before the shareholders' meeting.

Annual General Meeting 2024

At the Annual General Meeting held on 7 May 2024, it was decided in accordance with the Nomination Committee's proposal to re-elect Anders Ekblom, Hans-Peter Ostler, Eva Sjökvist Saers, Staffan Encrantz and Denise Goode as board members. Graham Dixon and Veronica Wallin have declined re-election. Furthermore, it was decided to re-elect Öhrlings PricewaterCoopers AB as the auditor. The Annual General Meeting resolved on fees to the Board in accordance with what appears under the heading "Remuneration to the Board" below.

Nomination Committee

The Code stipulates that Alligator should have a Nomination Committee whose duties should include preparing and producing proposals for the election of board members, the Chairman of the Board, the chair of the shareholders' meeting and the auditors. The Nomination Committee should also propose the fees payable to board members and auditors. At the Annual General Meeting on 9 May 2019, it was decided to adopt an instruction and rules of procedure for the Nomination Committee (valid until a decision is taken by the shareholders' meeting to change these) whereby the Nomination Committee should be made up of four members representing the three largest shareholders on the last working day of June, and the Chairman of the Board. The largest shareholders are owner-registered shareholders or other known shareholders as of the last working day in June. Before accepting the assignment, a member of the Nomination Committee should consider carefully whether there is any conflict of interest.

If any of the three largest shareholders declines to appoint a representative, or their representative leaves or steps down before completing the assignment without the shareholder that

appointed the member appointing a new one, the Chairman of the Board must invite the next-biggest shareholders in order of size down to the tenth largest (i.e. starting with the fourth-largest) to appoint a shareholder representative within one week of the request. If, despite such requests, only three members have been appointed four months before the Annual General Meeting, the Nomination Committee must be able to be constituted with three ordinary members and it must then be able to decide whether this procedure should be pursued to appoint the fourth member.

The members of the Nomination Committee should be published no later than six months before the Annual General Meeting on Alligator's website. In the event of significant changes of ownership earlier than six weeks before the Annual General Meeting, a new shareholder representative should be appointed. The Chairman of the Board should then contact whichever of the three largest shareholders has no shareholder representative and invite them to appoint one. When this shareholder representative is appointed, they should join the Nomination Committee and replace the previous member who no longer represents one of the three largest shareholders.

The Nomination Committee must meet the requirements for its composition laid down in the Code. If the larger shareholders who are entitled to appoint members of the Nomination Committee wish to appoint people who cause the requirements for the composition of the Committee laid down in the Code not to be satisfied, a larger shareholder will take precedence over a smaller in its choice of members. When a new member is appointed because of significant changes in ownership, the shareholder who is to appoint a new member must consider the composition of the existing Nomination Committee. The Nomination Committee should appoint its own chairperson. The Chairman of the Board or other Board representative may not chair the Nomination Committee. The mandate for the appointed Nomination Committee will run until a new Nomination Committee is appointed.

Fees may be paid to the members of the Nomination Committee as decided by the shareholders' meeting.

In accordance with the adopted instructions, the Nomination Committee for the 2025 Annual General Meeting has been constituted consisting of Bertil Brinck representing Koncentra Holding AB, (chairman of the Nomination Committee), Lars Bergkvist representing Roxette Photo SA, Magnus Petersson representing himself and Chairman of the Board, Anders Ekblom.

External audit

Alligator's auditor is appointed by the Annual General Meeting for the period up to the end of the next Annual General Meeting. The auditor reviews the annual report and accounts and the administration by the Board and the CEO. After each financial year, the auditor is required to submit an audit report to the shareholders' meeting.

Alligator's auditor reports his/her observations from the audit to the Board each year, along with an assessment of Alligator's internal control.

At the Annual General Meeting on 7 May 2024, Öhrlings PricewaterCoopers AB was elected as Alligator's auditor, with certified public accountant Ola Bjärehäll as auditor-in-charge. The Annual General Meeting also decided that fees should be paid to the auditor in accordance with the usual charging rules and approved invoices. The auditor's fee for the 2024 financial year was SEK 886 thousand, whereof SEK 704 thousand relates to the audit.

The Board of Directors

Duties of the Board

Next to the shareholders' meeting, the Board is Alligator's highest decision-making body. The Board is responsible for the organization of Alligator and the management of Alligator's affairs, e.g., by setting its goals and strategy, maintaining procedures and systems to monitor the specified goals, continuously assessing Alligator's economic situation and evaluating its operational management. The Board is also responsible for ensuring that correct information is given to Alligator's stakeholders, that Alligator complies with laws and regulations and that Alligator produces and implements internal policies and ethical guidelines. The Board also appoints Alligator's CEO and decides on his/her salary and other remuneration based on the guidelines adopted by the shareholders' meeting.

Composition of the Board

The members of the Board appointed by the shareholders' meeting are elected each year at the Annual General Meeting for the period up to the next Annual General Meeting. According to Alligator's articles of association, the Board should comprise at least three and at most eight members, without deputies.

According to the Code, most board members elected by the shareholders' meeting should be independent of Alligator and its senior management. To decide if a member is independent, an overall assessment should be made of all matters that could cast doubt on the member's independence of Alligator or its senior management. According to the Code, at least two of the members who are independent of Alligator and of its senior management should also be independent of major shareholders. Major shareholders are those who directly or indirectly control 10 percent or more of all shares and votes in Alligator. To determine a member's independence, the extent of that member's direct and indirect relationships with the major shareholder should be taken into consideration. A board member who is an employee or board member in a company that is a major shareholder is not considered to be independent.

The Board's assessment is that all proposed board members are independent in relation to Alligator and its senior management and all proposed board members except Staffan Encrantz

are also considered to be independent in relation to larger shareholders. As indicated, the Board believes Alligator meets the Code's independence requirements.

Chairman of the Board

The role of the Chairman is to lead the work of the Board, and to ensure that its work is carried out effectively and that the Board can meet all its obligations.

The Chairman should meet with the CEO to monitor developments in Alligator and ensure that the members of the Board are provided through the auspices of the CEO with the information needed to monitor Alligator's position, financial planning, and development.

The Chairman should also consult with the CEO on strategic matters and check that the decisions of the Board are implemented in an effective manner. The Chairman is responsible for contacts with shareholders on matters of ownership and for conveying the views of the shareholders to the Board. The Chairman is not involved in the day-to-day work of Alligator. Nor is he a member of senior management.

Work of the Board

The Board follows written procedure rules reviewed each year and adopted by the constituent board meeting. Among other things, the rules of procedure govern the Board's working

methods, tasks, decision-making within Alligator, the meeting schedule for the Board, the tasks of the Chairman and the breakdown of responsibilities between the Board and the CEO. The terms of reference for financial reporting and instructions to the CEO are also adopted at the constituent board meeting.

The work of the Board is also driven by an annual presentation schedule, to meet the Board's need for information. The Chairman and the CEO, along with the members of the Board, maintain an ongoing dialog on the management of Alligator.


The Board meets according to a predefined annual timetable and should hold at least seven ordinary board meetings between Annual General Meetings. Extra meetings may also be arranged to deal with matters that cannot be postponed to any of the ordinary meetings. In 2024, the Board met on a total of 32 occasions, whereof 8 meetings have been part of the normal annual wheel.

The yearly evaluation of the Board has been performed by individual interviews with Board members and senior management about their view on the Board's work, composition, and areas for improvement. The feedback has been reported back to the Nomination Committee and the Board consolidated.

Remuneration of the Board

Remuneration for Board members elected by the Annual General Meeting is decided by the Annual General Meeting.

Board meetings 2024



Board and committee members 2024

| Name | Position | Attendance | | |
|--------------------|--|------------|-----------------|------------------------|
| | | Board | Audit Committee | Remuneration Committee |
| Anders Ekblom | Chairman of the Board, Chair of the Remuneration Committee | 32/32 | | 4/4 |
| Hans-Peter Ostler | Vice Chairman of the Board, Chair of the Audit Committee | 32/32 | 5/5 | |
| Graham Dixon* | Board member, Member of the Remuneration Committee | 11/32 | | 2/4 |
| Eva Sjökvist Saers | Board member, Member of the Audit Committee | 31/32 | 5/5 | |
| Veronica Wallin* | Board member, Member of the Audit Committee | 13/32 | 3/5 | |
| Staffan Encrantz | Board member | 29/32 | | |
| Denise Goode | Board member, Member of the Remuneration Committee | 29/32 | | 4/4 |
| Anette Sundstedt* | Board member, Employee representative | 11/32 | | |
| Karin Nordbladh** | Board member, Employee representative | 29/32 | | |

*) Position(s) until and including the annual general meeting on 7 May 2024.

***) Position from and including the annual general meeting on 7 May 2024, previously deputy employee representative.

Ahead of the 2024 Annual General Meeting, the Nomination Committee will submit proposals regarding the fee. At the Annual General Meeting on 7 May 2024, it was resolved that board remuneration shall be paid with SEK 650,000 to the Chairman of the board of directors (SEK 650,000), with SEK 400,000 to the Vice Chairman of the board of directors (SEK 400,000) and with SEK 300,000 to each of the other board members who are not employed by Alligator (SEK 300,000). Furthermore, remuneration for committee work is proposed with SEK 125,000 to be paid to the Chairman of the Audit Committee (SEK 125,000), with SEK 50,000 to each of the other members of the Audit Committee (SEK 50,000), with SEK 50,000 to the Chairman of the Remuneration Committee (SEK 50,000) and with SEK 25,000 to each of the other members of the Remuneration Committee (SEK 25,000). See also Note 12, Remuneration to senior executives.

Audit Committee

The Audit Committee monitors Alligator's financial position and the effectiveness of its internal control and risk management, it keeps itself informed of the audit of the annual accounts and consolidated accounts and reviews and monitors the impartiality and independence of the auditor. The Audit Committee should also assist the Nomination Committee with resolutions on the election of and fees payable to the auditor. Following the Annual General Meeting on 7 May 2024, the Audit Committee consists of Hans-Peter Ostler (chairman) and Eva Sjökvist Saers.

Remuneration Committee

The Remuneration Committee chiefly addresses questions of remuneration and other conditions of employment of the CEO and senior executives. The Remuneration Committee should also follow up and evaluate ongoing variable remuneration schemes for senior management and those schemes completed during the year and follow up and assess compliance with the guidelines on remuneration of senior executives decided on by the Annual General Meeting. Following the Annual General Meeting on 7 May 2024, the Remuneration Committee consists of Anders Ekblom (chairman) and Denise Goode.

CEO and other senior executives

The CEO is subordinate to the Board and his main task is to handle Alligator's day-to-day management and operations. The rules of procedure for the Board and the instruction to the CEO set out the matters to be decided by the Board and those for which the CEO is responsible.

The CEO is also responsible for producing reports and decision-making documents ahead of the Board meetings, and for presenting this material at Board meetings.

Alligator's Management Team consists of four people: CEO, CFO, CMO and CTO.

Remuneration of senior executives

The remuneration of senior executives may consist of basic salary, variable remuneration, pension benefits, other benefits, and severance conditions. The CEO and other senior executives were paid salaries and other remuneration for the 2024 financial year as set out in Note 12.

The notice period for the CEO is six months, whichever party serves notice. The CEO will be entitled to a severance payment equal to six months' salary in the case of termination by Alligator. The notice period for other senior executives is three to six months, whichever party serves notice. No severance payments have been agreed for other senior executives.

See also **Guidelines for remuneration to senior executives on page 27** in the Annual report for 2024.

Internal control

The Board's responsibility for internal control is let down in the Companies Act, the Annual Accounts Act, which contains requirements to the effect that details of the major features of Alligator's systems for internal control and risk management in relation to financial reporting must be included in the corporate governance report, and the Code. Among other things, the Board is required to ensure that Alligator has good internal control and formalized procedures to ensure that the established principles for financial reporting and internal control are adhered to and that there are suitable systems for follow-up and control of Alligator's activities and the risks inherent in Alligator and its operations.

The overall purpose of internal control is to provide reasonable assurance that Alligator's operational strategies and goals are followed up and that the shareholders investments are protected. The internal control should also provide reasonable assurance that external financial reporting is reliable and prepared in accordance with good accounting practice, that applicable laws and regulations are obeyed and that requirements for listed companies are complied with. Internal control essentially covers the following five components:

Control environment

The Board bears the overall responsibility for internal control over financial reporting. In order to create and maintain a functioning control environment, the Board has adopted a number of policies governing financial reporting. These mainly comprise the rules of procedure for the Board, the mandate to the CEO and the terms of reference for financial reporting. The Board has also adopted a special set of signatory rules and a Financial Policy. Alligator also has a finance manual containing principles, guidelines, and process specifications for accounting and financial reporting. The Board has also set up an Audit Committee whose main task is to ensure that the approved principles for financial reporting and internal control are complied with and that regular contact with Alligator's auditor is maintained. The responsibility for maintaining an effective control environment and for the day-to-day work on internal control over financial reporting rests with the CEO. The CEO reports to the Board on a regular basis in accordance with the instruction to the CEO and the terms of reference for financial reporting. The Board also receives reports from Alligator's auditor.

Based on a control environment assessed as good, and the size of Alligator, the Board has determined that there are no special circumstances in the business or other matters to justify setting up an internal audit function.

Risk assessment

The risk assessment involves identifying risks that could arise if the fundamental requirements for financial reporting in Alligator were not met. In a separate risk assessment document, Alligator's Management Team has identified and evaluated the risks arising in Alligator's operations and assessed how these risks can be handled. Within the Board, the Audit Committee bears the primary responsibility for regularly assessing Alligator's risk situation, after which the Board carries out an annual review of the risk situation.

Control activities

Control activities contain identified risks and ensure correct and reliable financial reporting. The Board is responsible for internal control and monitoring by senior management. This is done via both internal and external control activities and through review and follow-up of Alligator's governing documents relating to risk management.

Information and communication

Alligator has information and communication paths designed to promote accuracy in financial reporting and to enable reporting and feedback from the business to the Board and senior management, such as by making governing documents in the form of internal policies, guidelines, and instructions available and known to the employees concerned. The Board has also adopted an information policy governing Alligator's disclosure of information.

Follow-up

Compliance with and effectiveness of the internal controls are followed up on a regular basis. The CEO ensures that the Board receives regular reports on the development of Alligator's operations, including the development of Alligator's results and financial position and details of significant events such as research findings and major agreements. The CEO also reports on these matters at each Board meeting.



Board of Directors



Anders Ekblom

Born 1954. Chairman since 2021 and Board member since 2017. Chairman of the Remuneration Committee.

Anders Ekblom is a physician, board certified in anesthesia and intensive care, dentist and Associate Professor in physiology at the Karolinska Institute. Anders Ekblom has extensive experience from the biopharmaceutical industry globally, including being EVP Global Medicines Development at AstraZeneca and CEO and president of AstraZeneca AB Sweden.

Other ongoing assignments: Chairman of Atrogi AB, Brf Sportspalatset and Xspray Pharma AB. Board member of AnaMar AB, Flerie AB, Flerie Invest AB, Mereo BioPharma Group plc, NxtScience AB and Synerkine Pharma B.V. Board alternate in Xspray Pharma Futurum AB.

Holdings in Alligator: 367,696 shares, 100,000 warrants in program TO 2022/2025 II, 240,000 warrants in program TO 2023/2026 II and 160,000 warrants in program TO 2024/2027 II.

Independent in relation to Alligator, its senior management and major shareholders.



Eva Sjökvist Saers

Born 1962. Board member since 2021. Member of the Audit Committee.

Eva Sjökvist Saers has a Doctoral degree in pharmaceutical science from Uppsala university. Eva Sjökvist Saers has many years of experience from the pharmaceutical industry where she has worked in various leading positions within Astra/AstraZeneca, Apoteket AB and as CEO of Apotek Produktion & Laboratorier AB for more than ten years. Eva Sjökvist Saers is also Chairman of the strategic innovation area Swelife and has previously been Chairman of Apotekarsocieteten and deputy chairman of SwedenBio.

Other ongoing assignments: Chairman of the Board of Coegin Pharma AB and Dicot Pharma AB. Board member of Apoex AB, Bluefish Pharmaceuticals AB and Oxclia AB. Board alternate in Brainstorm AB.

Holdings in Alligator: 100,000 warrants in program TO 2022/2025 II, 240,000 warrants in program TO 2023/2026 II and 160,000 warrants in program TO 2024/2027 II.

Independent in relation to Alligator, its senior management and major shareholders.



Hans-Peter Ostler

Born 1971. Deputy chairman of the Board and Board member since 2021. Chairman of the Audit Committee.

Hans-Peter Ostler has university studies in economics and law at the School of Business, Economics and Law and School of Public Administration at Gothenburg University. Hans-Peter Ostler has more than 20 years of experience in investment banking and private banking, including from Danske Bank. Hans-Peter Ostler's previous experiences include assignments such as board member of IRLAB Therapeutics AB

Other ongoing assignments: Chairman of Hoodin AB, NH3 Greentech AB and Vakona AB. Board member of Encare AB, Oblique Therapeutics AB and OPSY AB. Board alternate in O Mgmt AB. CEO of Tikomed AB.

Holdings in Alligator: 2,111,884 shares, 100,000 warrants in program TO 2022/2025 II, 240,000 warrants in program TO 2023/2026 II and 160,000 warrants in program TO 2024/2027 II.

Independent in relation to the Alligator, its senior management and major shareholders.



Denise Goode

Born 1958. Board member since 2022. Member of the Remuneration Committee.

Denise Goode has a Bachelor of Science (Honours) in zoology from the University of Manchester, UK. Fellow of the Institute of Chartered Accountants in England and Wales. Denise Goode, brings a wealth of financial, commercial, and life science industry experience, both from her extensive career as a senior pharmaceutical executive and from board and advisory roles held in life sciences since 2008. She has a deep understanding of the pharmaceuticals sector, finance and fundraising, and is highly experienced in business development. Previously, she had a 20-year career with AstraZeneca Pharmaceuticals PLC where she held global senior leadership roles within both finance and commercial activities. Denise is a PwC alumnus.

Other ongoing assignments: Board member of Abliva AB and CEO QED Life Science Ltd.

Holdings in Alligator: 100,000 warrants in program TO 2022/2025 II, 240,000 warrants in program TO 2023/2026 II and 160,000 warrants in program TO 2024/2027 II.

Independent in relation to Alligator, its senior management and major shareholders.



Staffan Encrantz

Born 1951. Board member since 2022.

Staffan Encrantz has a Law degree (Summa Cum Laude) from Uppsala University, Sweden. He is the founder and chairman of Allegro Investment, Inc., a company based in Menlo Park, California, which manages a \$750 million investment portfolio. He has actively led investments in and operation of a variety of companies for over 35 years and has led the growth and development of both early-stage companies and established businesses in a wide variety of fields. Additionally, Staffan has extensive experience in commercial real estate, primarily in Sweden and USA, and of the hedge fund industry as representing substantial investors in a number of hedge funds and as former Board member of MKM Longboat Multi Strategy Fund Ltd., Harbour Litigation Funding and Harbour Solutions Group Ltd.

Other ongoing assignments: Chairman of Allegro Investment Inc., AnaMar AB, Creston Water Solution Inc., GovX Inc. Koncentra AB, Koncentra Holding AB, Oxymetol SAS and Sight Sciences Inc. Board member of Allegro Fund GP Ltd, Koncentra Finans AB, KS Large Bore Pistons Group GmbH and Verkstads SMG AB. Managing member of Allegro Investors LLC, Allegro Properties, Inv. LLC and Parkfield Properties Holding LLC.

Holdings in Alligator: 249,948,629 shares through legal entity.

Independent in relation to Alligator and its senior management, but not in relation to major shareholders.



Karin Nordblad

Born 1979. Board member since 2024. Employee representative.

Master of Science in Pharmaceutical Bioscience from Uppsala University.

Other ongoing assignments: None.

Holdings in Alligator: 27,625 shares, 100,000 warrants in program TO 2022/2025 I, 180,000 warrants in program TO 2023/2026 I and 120,000 warrants in program TO 2024/2027 I.

Not independent in relation to Alligator or its senior management, but independent in relation to major shareholders.

Information regarding individuals' own and related parties' shareholdings pertain to the situation on 31 December 2024.

Management



**Søren
Bregenholt**

Born 1971. Chief Executive Officer since 2021.

Søren Bregenholt holds a PhD in biomedical research from University of Copenhagen and did his post-doctoral training at Institute Pasteur in Paris. Søren has more than 20 years of international experience from operational and strategic leadership positions in global pharma and the biotech industry including executive roles at Novo Nordisk, Symphogen and Macrophage Pharma. He has negotiated and operationalized numerous licensing, collaboration and co-development agreements.

Other ongoing assignments: Chairman of A Bioscience Incentive AB and Atlas Therapeutics AB. Board member of Oblique Therapeutics AB.

Holdings in Alligator: 1,103,019 shares, 500,000 warrants in program TO 2022/2025 I, and 1,200,000 warrants in program TO 2023/2026 I and 900,000 warrants in program TO 2024/2027 I.



**Johan
Giléus**

Born 1965. Chief Financial Officer since August 2024.

Johan Giléus has extensive experience as CFO with over 25 years of leading financial strategy and operations in different companies and sectors, including a major phase 3 program and outlicensing to Japan. Johan Giléus most recent experience is as CFO and Deputy CEO at InDex Pharmaceuticals, a company that conducted a reverse merger with Flerie Invest in 2024.

Studies in finance at Stockholm University.

Other ongoing assignments: Board member and CEO in Giléus Consulting AB and Giléus Invest AB.

Holdings in Alligator: None.



**Sumeet
Ambarkhane**

Born 1978. Chief Medical Officer since 2022.*

Sumeet Ambarkhane is an MD with a Bachelor of Medicine and a Bachelor of Surgery from Seth G.S. Medical College and King Edward Memorial Hospital, University of Mumbai, India. Sumeet is a seasoned professional with over 20 years of drug development experience in academia and in the biotechnology and pharmaceutical industries. Joined Alligator in 2022 and the Management Team in 2023.

Other ongoing assignments: None.

Holdings in Alligator: 54,205 shares and 250,000 warrants in program TO 2022/2025 I.



**Laura
von Schantz**

Born 1982. Chief Technology Officer since 2023.*

Laura von Schantz is a Swedish graduate engineer in biotechnical engineering and has a doctorate in immunotechnology from Lund University. Laura joined Alligator in 2014 and has played a key role in securing Alligator's research agreements. Employee representative in the Board during 2016-2023. Member of the Management Team since 2023.

Other ongoing assignments: None.

Holdings in Alligator: 10,504 shares and 77,000 warrants in program TO 2022/2025 I and 100,000 warrants in program TO 2024/2027 I.

Information regarding individuals' own and related parties' shareholdings pertain to the situation on 31 December 2024.

*) Senior executive will end its employment on 31 March 2025.